Cargando…

First‐Generation Bispidine Chelators for (213)Bi(III) Radiopharmaceutical Applications

Hepta‐ and octadentate bispidines (3,7‐diazabicyclo[3.3.1]nonane, diaza‐adamantane) with acetate, methyl‐pyridine, and methyl‐picolinate pendant groups at the amine donors of the bispidine platform have been prepared and used to investigate Bi(III) coordination chemistry. Crystal structure and solut...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bruchertseifer, Frank, Comba, Peter, Martin, Bodo, Morgenstern, Alfred, Notni, Johannes, Starke, Miriam, Wadepohl, Hubert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Full Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496608/ https://www.ncbi.nlm.nih.gov/pubmed/32613737 http://dx.doi.org/10.1002/cmdc.202000361

Ejemplares similares

Excited State Properties of Lanthanide(III) Complexes with a Nonadentate Bispidine Ligand
por: Abad‐Galán, Laura, et al.
Publicado: (2021)

Efficient formation of inert Bi-213 chelates by tetraphosphorus acid analogues of DOTA: towards improved alpha-therapeutics
por: Šimeček, Jakub, et al.
Publicado: (2018)

Versatile Bispidine‐Based Bifunctional Chelators for (64)Cu(II)‐Labelling of Biomolecules
por: Singh, Garima, et al.
Publicado: (2020)

Dual‐Nuclide Radiopharmaceuticals for Positron Emission Tomography Based Dosimetry in Radiotherapy
por: Wurzer, Alexander, et al.
Publicado: (2017)

Radium and Francium beam tests to produce 225Ac/ 213Bi generators at CERN-MEDICIS
por: Bruchertseifer, Frank, et al.
Publicado: (2015)

Pathways of the Extremely Reactive Iron(IV)‐oxido complexes with Tetradentate Bispidine Ligands
por: Abu‐Odeh, Mahmud, et al.
Publicado: (2021)

Long-Term Toxicity of (213)Bi-Labelled BSA in Mice
por: Dorso, Laëtitia, et al.
Publicado: (2016)

Diverse metabolic response of cancer cells treated with a (213)Bi-anti-EGFR-immunoconjugate
por: Feuerecker, Benedikt, et al.
Publicado: (2021)

Supply and Clinical Application of Actinium-225 and Bismuth-213
por: Morgenstern, Alfred, et al.
Publicado: (2020)

In Vitro comparison of (213)Bi- and (177)Lu-radiation for peptide receptor radionuclide therapy
por: Chan, Ho Sze, et al.
Publicado: (2017)

Alpha-Particle Emitting (213)Bi-Anti-EGFR Immunoconjugates Eradicate Tumor Cells Independent of Oxygenation
por: Wulbrand, Christian, et al.
Publicado: (2013)

Assessment of (213)Bi-anti-EGFR MAb treatment efficacy in malignant cancer cells with [1-(13)C]pyruvate and [(18)F]FDG
por: Feuerecker, Benedikt, et al.
Publicado: (2019)

An Overview of Targeted Alpha Therapy with (225)Actinium and (213)Bismuth
por: Morgenstern, Alfred, et al.
Publicado: (2018)

Optimizing labelling conditions of (213)Bi-DOTATATE for preclinical applications of peptide receptor targeted alpha therapy
por: Chan, Ho Sze, et al.
Publicado: (2016)

Influence of tumour size on the efficacy of targeted alpha therapy with (213)Bi-[DOTA(0),Tyr(3)]-octreotate
por: Chan, Ho Sze, et al.
Publicado: (2016)

Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with (213)Bi-substance P analogue
por: Krolicki, Leszek, et al.
Publicado: (2018)

Therapeutic efficacy of α-radioimmunotherapy with different activity levels of the (213)Bi-labeled monoclonal antibody MX35 in an ovarian cancer model
por: Gustafsson-Lutz, Anna, et al.
Publicado: (2017)

Cubosomal Lipid Formulation for Combination Cancer Treatment: Delivery of a Chemotherapeutic Agent and Complexed α-Particle Emitter (213)Bi
por: Cytryniak, Adrianna, et al.
Publicado: (2022)

Validation of Ab‐Initio‐Predicted Magnetic Anisotropies and Magneto‐structural Correlations in Linear Hetero‐trinuclear Dy(III)‐Ni(II) (2) Compounds
por: Comba, Peter, et al.
Publicado: (2021)

Therapeutic Efficacy of Alpha-RIT Using a (213)Bi-Anti-hCD138 Antibody in a Mouse Model of Ovarian Peritoneal Carcinomatosis
por: Derrien, Aurélie, et al.
Publicado: (2015)

Therapeutic Performance Evaluation of (213)Bi-Labelled Aminopeptidase N (APN/CD13)-Affine NGR-Motif ([(213)Bi]Bi-DOTAGA-cKNGRE) in Experimental Tumour Model: A Treasured Tailor for Oncology
por: Képes, Zita, et al.
Publicado: (2023)

α-Radioimmunotherapy with (213)Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma
por: Teiluf, Katharina, et al.
Publicado: (2014)

Treatment of Peritoneal Carcinomatosis by Targeted Delivery of the Radio-Labeled Tumor Homing Peptide (213)Bi-DTPA-[F3](2) into the Nucleus of Tumor Cells
por: Drecoll, Enken, et al.
Publicado: (2009)

Chelators for copper radionuclides in positron emission tomography radiopharmaceuticals()
por: Cai, Zhengxin, et al.
Publicado: (2013)

Hybrid Chelator-Based PSMA Radiopharmaceuticals: Translational Approach
por: Lahnif, Hanane, et al.
Publicado: (2021)

Modern Developments in Bifunctional Chelator Design for Gallium Radiopharmaceuticals
por: Davey, Patrick R. W. J., et al.
Publicado: (2022)

Targeted alpha therapy of mCRPC: Dosimetry estimate of (213)Bismuth-PSMA-617
por: Kratochwil, Clemens, et al.
Publicado: (2017)

Copper–Bispidine Complexes: Synthesis and Complex Stability Study
por: Medved’ko, Aleksei V., et al.
Publicado: (2016)

Level structure in $^{213}Bi$
por: Chumin, V G, et al.
Publicado: (1996)

(213)Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience
por: Kratochwil, C., et al.
Publicado: (2014)

Click-to-Chelate: Development of Technetium and Rhenium-Tricarbonyl Labeled Radiopharmaceuticals
por: Kluba, Christiane A., et al.
Publicado: (2013)

AAZTA-Derived Chelators for the Design of Innovative Radiopharmaceuticals with Theranostic Applications
por: Fersing, Cyril, et al.
Publicado: (2022)

Bispidine Platform as a Tool for Studying Amide Configuration Stability
por: Krut’ko, Dmitry P., et al.
Publicado: (2022)

DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay
por: Schmeiser, Heinz H, et al.
Publicado: (2019)

It’s Time to Shift the Paradigm: Translation and Clinical Application of Non-αvβ3 Integrin Targeting Radiopharmaceuticals
por: Kossatz, Susanne, et al.
Publicado: (2021)

Therapeutic Radiopharmaceuticals Targeting Integrin αvβ6
por: Färber, Stefanie Felicitas, et al.
Publicado: (2018)

Anticancer Cytotoxic Activity of Bispidine Derivatives Associated with the Increasing Catabolism of Polyamines
por: Neborak, Ekaterina V., et al.
Publicado: (2022)

Studies of $\alpha$-spectra in $^{221}Fr, ^{217}At, ^{213}Bi$ and $^{213}Po$ decays
por: Chumin, V G, et al.
Publicado: (1997)

A Radionuclide Generator of High-Purity Bi-213 for Instant Labeling
por: Ermolaev, Stanislav, et al.
Publicado: (2021)

Hydroxypyridinone Chelators: From Iron Scavenging to Radiopharmaceuticals for PET Imaging with Gallium-68
por: Cusnir, Ruslan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_mr8qdbb7uo28hubcagpmohaq84